clinical trial · NCT07503405
Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
InfluenzaTRX-100PlaceboInfluenza A/France/759/2021 (H1N1) virus
brief summary
This will be a randomized, double-blind, placebo-controlled proof of concept study to evaluate the prophylactic efficacy and safety of orally administered TRX-100 in healthy adults challenged with influenza A/France/759/2021 (H1N1) virus.
started
Jun 1, 2026
primary completion
Nov 1, 2026
completion
Apr 1, 2027
last updated
Mar 31, 2026
detailed description
This is a Phase 2a study in healthy adult participants between 18 and 55 years of age. Study design is a single-center, randomized, double-blind, placebo-controlled study to evaluate the prophylactic efficacy and safety of TRX-100 followed by inoculation with influenza A challenge agent in healthy adults.
official title
A Phase 2a, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tivoxavir Marboxil (TRX-100) in Healthy Adults in a Human Influenza A Challenge Model
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol